Research programme: peptide-coated BCG based cancer vaccines - Valo Therapeutics
Alternative Names: PeptiBAC cancer vaccines - Valo TherapeuticsLatest Information Update: 28 May 2025
At a glance
- Originator University of Helsinki
- Developer University of Helsinki; Valo Therapeutics
- Class Cancer vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Cancer in Finland (Parenteral)
- 19 Apr 2021 Peptide-coated BCG based cancer vaccines - Valo Therapeutics is available for licensing as of 19 Apr 2021. https://www.valotx.com/
- 19 Apr 2021 Valo Therapeutics acquires PeptiBAC technology from the University-of-Helsinki